NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Investors of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its Board of Directors has authorized a stock repurchase plan on Saturday, December 2nd 2017, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's board believes its stock is undervalued.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Tuesday, May, 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to analysts' expectations of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. The firm's revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.88 EPS. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 brokerages have issued 1-year price targets for Merck & Co., Inc.'s shares. Their forecasts range from $58.83 to $72.00. On average, they expect Merck & Co., Inc.'s stock price to reach $66.0519 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Ratings for Merck & Co., Inc..

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Merck & Co., Inc. saw a decrease in short interest in June. As of June 29th, there was short interest totalling 17,153,866 shares, a decrease of 21.6% from the June 15th total of 21,867,505 shares. Based on an average daily trading volume, of 11,109,077 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.6% of the company's stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about MRK stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the company an impact score of 44.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Merck & Co., Inc.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), Bank of Montreal Can (0.14%), NN Investment Partners Holdings N.V. (0.08%), Manning & Napier Group LLC (0.07%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Manning & Napier Group LLC, Radnor Capital Management LLC, Clinton Group Inc., Fulton Bank N.A., Fjarde AP Fonden Fourth Swedish National Pension Fund, Swedbank and Lodestar Investment Counsel LLC IL. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, LGT Capital Partners LTD., DnB Asset Management AS, Welch & Forbes LLC, Handelsbanken Fonder AB, Sabal Trust CO and Gofen & Glossberg LLC IL. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $62.59.

Merck & Co., Inc. has a market capitalization of $169.56 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]